Send to

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2013 Sep 1;2(9):e25801. Epub 2013 Jul 29.

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4+ and CD8+ T cells.

Author information

Department of Immunogenetics, Graduate School of Medical Sciences; Kumamoto University; Kumamoto, Japan ; Department of Respiratory Medicine; Graduate School of Medical Sciences; Kumamoto University; Kumamoto, Japan.


CD4+ T cells promote cytotoxic T lymphocyte (CTL)-mediated anticancer immune responses. We have recently identified ideal tumor-associated antigen (TAA)-derived long peptides (LPs) that elicit not only TAA-specific TH1 response, but also CTLs, through cross-presentation. The LP-specific TH1 cell responses were augmented in cancer patients vaccinated with CTL epitopes. Our findings support the clinical application of LP-based immunotherapy.


Type 1 helper T cell; cDNA microarray analysis; cross-presentation; helper T-cell epitope; peptide vaccine; tumor-associated antigen

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center